Reuters logo
BRIEF-Glycyx Pharmaventures and Valeant agree to terms of licensing agreement in oncology
March 15, 2017 / 5:28 PM / in 7 months

BRIEF-Glycyx Pharmaventures and Valeant agree to terms of licensing agreement in oncology

March 15 (Reuters) - Glycyx Pharmaventures :

* Glycyx Pharmaventures and Valeant Pharmaceuticals agree to binding terms of licensing agreement in the field of oncology

* Deal allows co to commercialize products containing Methylnaltrexone Bromide for oncology indications in countries outside US, Canada

* Glycyx would pay sales-based milestones and royalties to Valeant Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below